Competing-risks model for predicting the prognosis of penile cancer based on the SEER database

Jin Yang1,2 | Zhenyu Pan1,2,3 | Yujing He4 | Fanfan Zhao1,2 | Xiaojie Feng1,2 | Qingqing Liu1,2 | Jun Lyu1,2

Abstract

Objectives: This study performed a competing-risks analysis using data from the SEER database on penile cancer patients with the aim of identifying more accurate prognostic factors.

Methods: Data on patients with penile cancer were extracted from the SEER database. A univariate analysis used the cumulative incidence function and Gray's test, while multivariate analysis was performed using the Fine-Gray model. Cumulative hazards were compared with a competing-risks model constructed using Kaplan-Meier estimation.

Results: The multivariate Fine-Gray analysis indicated that being black (HR = 1.51, 95%CI: 1.10-2.07, \( P = .01 \)), AJCC stage II (HR = 1.94, 95%CI: 1.36-2.77, \( P < .001 \)), AJCC stage III (HR = 1.98, 95%CI: 1.34-2.91, \( P < .001 \)), tumor size > 5 cm (HR = 2.23, 95%CI: 1.33-3.72, \( P < .05 \)), and TNM stages N1 (HR = 2.49, 95%CI: 1.71-3.61, \( P < .001 \)), N2 (HR = 3.25, 95%CI: 2.18-4.84, \( P < .001 \)), N3 (HR = 5.05, 95%CI: 2.69-9.50, \( P < .001 \)), and M1 (HR = 2.21, 95%CI: 1.28-3.84, \( P < .05 \)) were statistically significant. The results obtained using multivariate Cox regression were different, while Kaplan-Meier curve analysis led to an overestimation of the cumulative risk of the patient.

Conclusions: This study established a competing-risks analysis model for the first time based on the SEER database for the risk assessment of penile cancer patients. The results may help clinicians to better understand penile cancer and provide these patients with more appropriate support.

KEYWORDS

competing-risks model, fine-gray, penile cancer, prognostic factors, SEER database
1 | INTRODUCTION

Cancers of the male genital system account for nearly one-third of all cancers in males, including prostate, testicular, and penile cancers. Penile cancer is a malignant tumor that is rare in developed countries, especially in the United States and in European countries. The morbidity and mortality rates of penile cancer have been low and stable in Nordic countries. There were 2030 new cases of penile cancer in the United States in 2016, with 340 deaths. In contrast, penile cancer accounts for 10%-20% of malignant tumors in males in Africa, Asia, and South America.

Squamous cell carcinoma is the most common malignant lesion of the penis. Although there have been some reports of risk factors associated with penile cancer survival, most of them were based on Cox proportional-hazards regression models and Kaplan-Meier estimates. Performing a follow-up or making observations of a two-state model from a start event to an event of interest is a common design and analysis strategy, and Kaplan-Meier estimates, log-rank tests, and Cox regression are widely used for such single events of interest. However, those statistical analyses involve only one type of event. In medical research, the observed endpoints are rarely single, but there are multiple endpoints. The occurrence of competing events “blocks” the occurrence of the ending event of interest and forms a “competing relationship.” For example, in cardiovascular disease mortality studies, patients may die from cardiovascular disease or die from other causes such as cancer, suicide, etc. The frequency of comorbidities may be especially high in older people; for example, the risk of death from heart disease and cerebrovascular disease increases with age in patients with nonsmall-cell lung cancer. Traditional survival analysis will treat such competing risks by censoring, which will lead to miscalculations of the survival function. This is because the Kaplan-Meier method and the Cox method treat other competing events as censored, and there may be conclusions that are estimated to be high or even contrary with the facts, also called competitive risk bias. These considerations indicate the need to use a competing-risks model to handle multiple endpoints.

This study conducted a competing-risks analysis using data from the SEER database on penile cancer patients with the aim of identifying more accurate prognostic factors.

2 | METHODS AND MATERIALS

2.1 | Patients

Data on patients with penile cancer were extracted from the SEER database using version 8.3.5 of the SEER*Stat software. The SEER program includes 18 registries that cover 30% of the United States population and collects demographic, clinical, and outcome information on all cancers diagnosed in representative geographic regions and sub-populations of the United States. We queried the SEER program database for records from 2004 to 2015 using inclusion criteria of an age at diagnosis ≥ 18 years and the following site codes of the International Classification of Diseases for Oncology, Third Edition (ICD-O-3): C60.1 (glans penis), C60.2 (body of penis), C60.8 (overlapping lesion of penis), and C60.9 (penis NOS). The exclusion criteria were (a) no surgery, diagnosis, or microscopy confirmation, (b) only autopsy findings, or (c) incomplete variables.

The following information was collected for each patient: age at diagnosis, race, marital status, AJCC stage, surgery status, radiation status, tumor size, N stage, M stage, examination status of regional lymph nodes, primary site, survival time, and cause of death. We adopted the sixth edition of the AJCC staging system since this was used for recording data in the SEER database from 2004.

2.2 | Statistical analysis

Continuous data are presented as the mean ± standard-deviation values, and categorical data are presented as frequencies and proportions. We regarded other causes of death as competing events in our analysis of competing risks. When there is a competing risk, the outcome is not only survival, death. Cumulative incidence function, \( \text{CIF}_k(t) = \Pr(T \leq t, D = k) \), represents the probability of the k event before time t and other types of events. The comparison between the cumulative incidences of the groups is checked by the Gray test. Univariate analysis was performed using the cumulative incidence function (CIF) to show the probability of each event and Gray’s test to estimate the difference in the CIF between groups. Multivariate analysis with the Fine-Gray model was used to identify factors affecting the cumulative incidence of penile cancer. The Fine-Gray model is designed to fit the cumulative incidence of events of interest. It is suitable for personal risk prediction research, tends to estimate disease risk and prognosis, and is suitable for establishing clinical prediction models and risk scores. We also compared the results from a Cox regression model with those from the Fine-Gray model. The cumulative hazard was compared with a competing-risks model constructed using Kaplan-Meier estimation. Finally, according to the Bayesian information standard, we repeated the multivariate analysis using age as a time-varying covariate.

All statistical analyses were performed using SPSS (version 24.0, SPSS), Empower Stats (version 2018-12-22; http://www.empowerstats.com/cn/), and R statistical software (version 3.5.0; https://www.r-project.org/). The “cmprsk” R package was used to construct the model. All statistical tests were two-sided, with \( P < .05 \) considered to be indicative of statistical significance.
The SEER database can be accessed free of charge, and this study was exempted from obtaining informed consent from the included patients by the institutional research committee of the First Affiliated Hospital of Xi’an Jiaotong University.

3 | RESULTS

3.1 | Patient characteristics

Of the 2091 eligible patients, 541 died of other causes such as other cancers, suicide, and accidents, accounting for 25.87% of the total. Death due to other reasons was considered a competing event; 333 died of penile cancer, accounting for 15.93% of the total. Those who died of penile cancer were aged 66.00 ± 13.85 years. Most of the patients were married (n = 191, 15.4%), were AJCC stage III (n = 97, 22.7%), had received surgery (n = 314, 15.6%), had not received radiation or had an unknown radiation status (n = 280, 14.7%), had a tumor size of >3 cm and ≤5 cm (n = 118, 19.1%), were TNM stage N0 (n = 171, 10.3%), were TNM stage M0 (n = 302, 14.9%), had not had their regional lymph nodes examined (n = 193, 12.7%) and had an ICD-O-3 code of C60.9 (penis NOS) at the primary site (n = 158, 16.0%). The median follow-up time was 27 months. The results are provided in detail in Table 1 and Figure 1.

3.2 | Univariate analysis of the prognosis of penile cancer

The univariate analysis included Gray’s test and the CIF. When competing risks were present, the results of Gray’s test showed that age, race, AJCC stage, surgery status, radiation status, tumor size, N stage, M stage, and the examination status of regional lymph nodes exerted statistically significant effects on penile cancer (P < .05). The CIF for almost all variables increased over 1, 3, and 5 years, and was higher for larger tumors and in black patients, unmarried patients, and patients who had not undergone surgery, had received radiation, and had had their regional lymph nodes examined. The CIF values in AJCC stages I, II, III, IV were 2.5%, 7.0%, 12.1%, and 34.2% respectively (P < .001). There was also a significant difference in the degree of lymphatic metastasis and a CIF of death from penile cancer (P < .001). The CIF was 56.2% for a follow-up time of 5 years for distant metastasis. The data are listed in detail in Table 2.

3.3 | Multivariate analysis of the prognosis of penile cancer

When competing events were present, we included variables that were statistically significant in the univariate analysis in the Fine-Gray model. The multivariate analysis

| Variables          | ALL   | Death to penile cancer | Death to other reasons |
|--------------------|-------|------------------------|------------------------|
| Age                | 67 ± 14.24 | 66 ± 13.85           | 75 ± 11.79            |
| Race               |        |                        |                        |
| White              | 1772   | 274 (15.5)            | 450 (25.4)            |
| Black              | 201    | 44 (21.9)             | 53 (26.4)             |
| Other              | 118    | 15 (12.7)             | 38 (32.2)             |
| Marital status     |        |                        |                        |
| Married            | 1242   | 191 (15.4)            | 299 (24.1)            |
| Unmarried          | 381    | 64 (16.8)             | 76 (19.9)             |
| DSW                | 468    | 78 (16.7)             | 166 (35.5)            |
| AJCC stage         |        |                        |                        |
| I                  | 922    | 64 (6.9)              | 237 (25.7)            |
| II                 | 543    | 89 (16.4)             | 147 (27.1)            |
| III                | 428    | 97 (22.7)             | 110 (25.7)            |
| IV                 | 198    | 83 (41.9)             | 47 (23.7)             |
| Surgery            |        |                        |                        |
| Yes                | 2012   | 314 (15.6)            | 515 (25.6)            |
| No/Unknown         | 79     | 19 (24.1)             | 26 (32.9)             |
| Radiation          |        |                        |                        |
| Yes                | 182    | 53 (29.1)             | 43 (23.6)             |
| No/Unknown         | 1909   | 280 (14.7)            | 498 (26.1)            |
| Tumor size(cm)     |        |                        |                        |
| ≤1                 | 237    | 18 (7.6)              | 52 (21.9)             |
| 1 < T≤ 3           | 866    | 103 (11.9)            | 224 (25.9)            |
| 3 < T≤5            | 617    | 118 (19.1)            | 171 (17.7)            |
| >5                 | 371    | 94 (25.3)             | 94 (25.3)             |
| N                  |        |                        |                        |
| N0                 | 1661   | 171 (10.3)            | 448 (27.0)            |
| N1                 | 144    | 43 (29.9)             | 36 (25.0)             |
| N2                 | 159    | 59 (37.1)             | 30 (18.9)             |
| N3                 | 127    | 60 (47.2)             | 27 (21.3)             |
| M                  |        |                        |                        |
| M0                 | 2025   | 302 (14.9)            | 525 (25.9)            |
| M1                 | 66     | 31 (47.0)             | 16 (24.2)             |
| Regional nodes examined | | | |
| Yes                | 573    | 140 (24.4)            | 97 (16.9)             |
| No                 | 1518   | 193 (12.7)            | 444 (29.2)            |
| Primary site       |        |                        |                        |
| Glans penis        | 861    | 136 (15.8)            | 216 (25.1)            |
| Body of penis      | 134    | 19 (14.2)             | 38 (28.4)             |
| Overlapping lesion of penis | 108   | 20 (18.5)            | 30 (27.8)             |
| Penis NOS          | 988    | 158 (16.0)            | 257 (26.0)            |

Abbreviations: AJCC, American Joint Committee on Cancer; DSW, divorced & separated & widowed; NOS, not otherwise specified.
indicated that being black, AJCC stage II, AJCC stage III, tumor size > 5 cm, and TNM stages N1, N2, N3, and M1 were significantly associated with survival. The data are listed in detail in Table 3, which includes the results from the multivariate Cox regression for comparison. Due to age as a prognostic factor changing with time and causing variations in other prognostic factors, we repeated the Fine-Gray analysis using age as a time-varying covariate. Variables in multiple categories in that analysis were converted into two-category dummy variables. In the presence of competing risks, a stepwise regression method is used for screening based on Bayesian information criteria. The results showed that when age was used as a time covariate, AJCC stage II (vs AJCC stage I: hazard ratio [HR] = 1.85, 95% confidence interval [CI] = 1.30-2.63, \( P < .001 \)), AJCC stage III (vs AJCC stage I: HR = 1.88, 95% CI = 1.29-2.74, \( P < .001 \)), tumor size > 5 cm (vs tumor size ≤ 1 cm: HR = 2.35, 95% CI = 1.40-3.94, \( P < .05 \)), TNM stage N1 (vs TNM stage N0: HR = 2.24, 95% CI = 1.58-3.19, \( P < .001 \)), TNM stage N2 (vs TNM stage N0: HR = 2.96, 95% CI = 2.04-4.28, \( P < .001 \)), TNM stage N3 (vs TNM stage N0: HR = 4.60, 95% CI = 2.50-8.45, \( P < .001 \)), and TNM stage M1 (vs TNM stage M0: HR = 2.13, 95% CI = 1.23-3.70, \( P < .05 \)) exerted statistically significant effects in penile cancer. Significant differences were also found in the stratification of each prognostic factor (Figure S1). Neither the linear term (relative risk [RR] = 1.00, \( P = .73 \)) nor the quadratic term (RR = 1.00, \( P = .62 \)) expressing the interaction of time with age was statistically significant. The data are listed in detail in Table 4.

### 3.4 Comparative analysis

We compared the results from classical Kaplan-Meier curve analysis with the cumulative risk rate of the competing-risks model, which revealed that only Kaplan-Meier curve analysis led to an overestimation of the cumulative risk of the patient (Figure 2A). The results show that, in fact, when there is a risk of competition, the cumulative risk of penile cancer patients is not as high as the cumulative risk of the K-M method. As can be seen from Figure 2B, the cumulative incidence due to death from other causes for the same survival time was higher than that from penile cancer alone. If death from other causes is treated as censored, it will have a greater impact on the results.
| Variables                | Gray's test | P-value | Cumulative incidence function | 12-mo | 36-mo | 60-mo |
|-------------------------|-------------|---------|--------------------------------|-------|-------|-------|
| Age                     | 116.37      | <.05    |                                |       |       |       |
| Race                    | 6.46        | .04     |                                |       |       |       |
| White                   | 0.08        | .16     | 0.19                           |       |       |       |
| Black                   | 0.12        | .23     | 0.25                           |       |       |       |
| Other                   | 0.06        | .13     | 0.14                           |       |       |       |
| Marital status          | 1.07        | .59     |                                |       |       |       |
| Married                 | 0.09        | .17     | 0.20                           |       |       |       |
| Unmarried               | 0.10        | .19     | 0.20                           |       |       |       |
| DSW                     | 0.08        | .17     | 0.20                           |       |       |       |
| AJCC Stage              | 206.07      | <.001   |                                |       |       |       |
| I                       | 0.03        | 0.07    | 0.09                           |       |       |       |
| II                      | 0.07        | 0.16    | 0.20                           |       |       |       |
| III                     | 0.12        | 0.24    | 0.27                           |       |       |       |
| IV                      | 0.34        | 0.45    | 0.45                           |       |       |       |
| Surgery                 | 4.98        | .03     |                                |       |       |       |
| Yes                     | 0.08        | 0.16    | 0.19                           |       |       |       |
| No/Unknown              | 0.16        | 0.25    | 0.27                           |       |       |       |
| Radiation               | 28.08       | <.001   |                                |       |       |       |
| Yes                     | 0.17        | 0.32    | 0.34                           |       |       |       |
| No/Unknown              | 0.08        | 0.15    | 0.17                           |       |       |       |
| Tumor size(cm)          | 63.20       | <.001   |                                |       |       |       |
| ≤1                      | 0.03        | 0.08    | 0.09                           |       |       |       |
| 1 < T ≤ 3               | 0.05        | 0.11    | 0.14                           |       |       |       |
| 3 < T ≤ 5               | 0.10        | 0.28    | 0.30                           |       |       |       |
| >5                      | 0.19        | 0.28    | 0.30                           |       |       |       |
| N                       | 251.70      | <.001   |                                |       |       |       |
| N0                      | 0.05        | 0.07    | 0.13                           |       |       |       |
| N1                      | 0.11        | 0.20    | 0.37                           |       |       |       |
| N2                      | 0.24        | 0.35    | 0.45                           |       |       |       |
| N3                      | 0.40        | 0.49    | 0.53                           |       |       |       |
| M                       | 89.92       | <.001   |                                |       |       |       |
| M0                      | 0.07        | 0.15    | 0.18                           |       |       |       |
| M1                      | 0.49        | 0.56    | 0.56                           |       |       |       |
| Regional nodes examined | 45.36       | <.001   |                                |       |       |       |
| Yes                     | 0.12        | 0.25    | 0.29                           |       |       |       |
| No                      | 0.07        | 0.13    | 0.15                           |       |       |       |
| Primary site            | 1.17        | .76     |                                |       |       |       |
| Glans penis             | 0.08        | 0.16    | 0.19                           |       |       |       |
| Body of penis           | 0.07        | 0.16    | 0.19                           |       |       |       |
| Overlapping lesion of penis | 0.09   | 0.18    | 0.23                           |       |       |       |
| Penis NOS               | 0.09        | 0.16    | 0.19                           |       |       |       |

Abbreviations: AJCC, American Joint Committee on Cancer; DSW, divorced & separated & widowed; NOS, not otherwise specified.

Bold values means that P < .05.
Single endpoints are rarely observed in medical research, with instead multiple endpoints that compete with each other commonly being present. The occurrence of competing events hinders analyses of the occurrence of ending events of interest in a study. Previous studies have widely used Kaplan-Meier estimates of survival curves and Cox regression models to describe survival trends and identify important prognostic factors. In the real world, the research

| Variables                      | Fine-Gray regression analysis | COX regression analysis |
|--------------------------------|-------------------------------|------------------------|
|                                | HR (95% CI)                   | HR (95% CI)            |
|                                | P-value                        | P-value                |
| Age                            | 1.00 0.99-1.00 .44            | 1.04 1.03-1.05 <.001   |
| Race                           |                               |                        |
| White                          | Reference                      | Reference              |
| Black                          | 1.51 1.10-2.07 .01            | 1.38 1.11-1.71 <.05    |
| Other                          | 0.74 0.45-1.22 .23            | 1.05 0.79-1.38 .77    |
| Marital status                 |                               |                        |
| Married                        | …                              | Reference              |
| Unmarried                      |                                | 1.16 0.96-1.42 .13    |
| DSW                            |                                | 1.19 1.01-1.34 .03    |
| AJCC Stage                     |                               |                        |
| I                              | Reference                      | Reference              |
| II                             | 1.94 1.36-2.77 <.001          | 1.15 1.00-1.44 .17    |
| III                            | 1.98 1.34-2.91 <.001          | 1.33 1.07-1.64 .010   |
| IV                             | 1.64 0.87-3.12 .13            | 1.45 0.95-2.21 .08    |
| Surgery                        |                               |                        |
| Yes                            | 0.86 0.52-1.44 .57            | 0.63 0.46-0.86 <.05   |
| No/Unknown                     | Reference                      | Reference              |
| Radiation                      |                               |                        |
| Yes                            | 1.13 0.82-1.58 .45            | 0.98 0.78-1.23 .83    |
| No/Unknown                     | Reference                      | Reference              |
| Tumor size(cm)                 |                               |                        |
| ≤1                             | Reference                      | Reference              |
| 1 < T≤ 3                       | 1.24 0.76-2.04 .39            | 1.33 1.02-1.72 .03    |
| 3 < T≤5                        | 1.55 0.93-2.57 .09            | 1.62 1.23-2.12 <.05   |
| >5                             | 2.23 1.33-3.72 <.05           | 2.00 1.50-2.67 <.001  |
| N                              |                               |                        |
| N0                             | Reference                      | Reference              |
| N1                             | 2.49 1.71-3.61 <.001          | 1.71 1.33-2.00 <.001  |
| N2                             | 3.25 2.18-4.84 <.001          | 1.73 1.32-2.26 <.001  |
| N3                             | 5.05 2.69-9.50 <.001          | 2.72 1.48-3.22 <.001  |
| M                              |                               |                        |
| M0                             | Reference                      | Reference              |
| M1                             | 2.21 1.28-3.84 <.05           | 2.18 1.48-3.22 <.001  |
| Regional nodes examined        |                               |                        |
| Yes                            | 0.81 0.61-1.07 .14            |                        |
| No                             | Reference                      |                        |

**Table 3**: Multivariable analysis in patients with penile cancer

Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; DSW, divorced & separated & widowed; HR, hazard ratio; NOS, not otherwise specified. Bold values mean that P < .05.
object not only experiences one type of event, but different types of ending events affect each other, that is, form competing events. The statistical model for processing data with competitive events is called the “competing risk model.” Survival data positive events usually include all-cause death and cause-specific death. When the study does not involve competing risks, K-M, COX regression method can be used for research. However, medical research generally has competing events. When discussing specific causes of death, the traditional method may overestimate the cumulative incidence of each variable. It is therefore necessary to use the competing-risks model to deal with multiple end events.23,24

In our study, competing risk analysis did not consider events due to penile cancer death. It also considers events that die for other reasons and the effects of events.

Penile cancer is a relatively rare malignant tumor in the United States, and a delayed or missed diagnosis can lead to post treatment dysfunction and reduced survival.25,26

Our study included 874 penile cancer patients who had died between 2004 and 2015, with 541 dying of other causes such as other cancers, suicides, and accidents, while 333 had died of their penile cancer. This means that less than two-thirds of the results of interest, indicating the need to apply a competing-risks model. Two main methods are currently used to analyze competing risks: the cause risk model and the cumulative risk model. The cumulative risk model considers other competing endpoint events simultaneously when calculating an endpoint event of interest, which is more realistic. The present study is the first to conduct a risk analysis of penile cancer patients using a cumulative risk model in a competing-risks model and thereby identifying more accurate prognostic factors.

Sharma et al found that being black was associated with worse overall survival among penile cancer patients (HR = 1.39, 95% CI = 1.21-1.58, P < .01),27 while Slopnick et al found that that African-American penile cancer patients had higher mortality rates than white patients (HR = 1.25, 95% CI = 1.10-1.42, P < .001).28 These results are based only on Cox regression analysis and are similar to our Cox regression results (HR = 1.38, 95% CI = 1.11-1.72, P < .05), and our Fine-Gray regression analysis revealed that the Cox regression model underestimated the risk of black race (HR = 1.51, 95% CI = 1.10-2.07, P < .05).

The Cox regression model also underestimates the risk of the AJCC stage. The Fine-Gray model revealed that AJCC stage II (HR = 1.94, 95% CI = 1.36-2.77, P < .001) and AJCC stage III (HR = 1.98, 95% CI = 1.34-2.91, P < .001) were risk factors for death in penile cancer patients compared with AJCC stage I. However, in the Cox regression, we did not observe statistical significance for AJCC stage II, and the HR for AJCC stage III was only 1.33. The HR for AJCC stage IV was >1 in both the Fine-Gray model and the Cox regression model, although we did not find that AJCC stage IV was statistically significant. We believe that these findings may have resulted from the interaction of multiple variables included in the model, and so these relationships need to be explored further.

The Fine-Gray model indicated that the p value was statistically significant only for a tumor size of >5 cm. The N stage is a very significant prognostic factor, with lymph node metastasis long having been considered an important prognostic factor for penile cancer.29,30 TNM stages N0, N1, N2, and N3 all significantly affect survival in the present study, whereas Cox regression underestimated the risk of the N stage. Finally, we also found that distant metastasis is a risk factor affecting patient survival (HR = 2.22, 95% CI = 1.28-3.84, P < .05). These observations indicate that the relative risk of a patient dying from penile cancer when a competing event is present is different from when considering only a single endpoint event.

Our univariate analysis indicated that age was a statistically significant factor. Since age increases over time and so may result in changes in other prognostic factors, we performed a multivariate analysis of age as a time-varying covariate. The results showed that AJCC stage II, AJCC stage

| Table 4 | Multivariable analysis by Bayesian Information |
|---------|-----------------------------------------------|
| Variables | HR (95% CI) | P-value |
| Age | 1.00 | 1.00-1.00 | .73 |
| Age | 1.00 | 1.00-1.00 | .62 |
| AJCC stage | | |
| I | Reference | |
| II | 1.85 | 1.30-2.63 | <.001 |
| III | 1.88 | 1.29-2.74 | <.001 |
| IV | 1.76 | 0.88-3.18 | .12 |
| Tumor size(cm) | | |
| ≤1 | Reference | |
| 1 < T ≤ 3 | 1.30 | 0.79-2.14 | .30 |
| 3 < T ≤ 5 | 1.64 | 0.99-2.73 | .06 |
| >5 | 2.35 | 1.40-3.94 | <.05 |
| N | | |
| N0 | Reference | |
| N1 | 2.24 | 1.58-3.19 | <.001 |
| N2 | 2.96 | 2.04-4.28 | <.001 |
| N3 | 4.60 | 2.50-8.45 | <.001 |
| M | | |
| M0 | Reference | |
| M1 | 2.13 | 1.23-3.70 | <.05 |

Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; HR, hazard ratio.

* Age was used as time-varying covariates.

Bold values means that P < .05.
III, tumor size > 5 cm, and TNM stages N1, N2, N3, and M1 were significantly associated with survival. Age was not an independent prognostic factor affecting survival and its effect did not change over time. This is the first study to use the competing-risks model to analyze the survival of patients with penile cancer. While we conclude from the present results that age is not a prognostic factor for patients, this relationship needs to be studied further.

When a competing event exists, the incidence of events of interest at time \( t \) in the cumulative risk model is conditional on the composite event rate of all events of interest and those competing events, whereas the Kaplan-Meier estimation is only conditional on the incidence of events of interest. We compared the results from classical Kaplan-Meier curve analysis with the cumulative risk rate of the competing-risks model. When a competing event is treated as censored data, using the Kaplan-Meier method to calculate the cumulative risk results in a larger effect than the cumulative risk calculated using the competing-risks model, thereby overestimating the actual situation.

One major strength of the present study was that the SEER database provides a very large number of samples to explore risk factors and construct accurate competing-risks models. However, it is undeniable that our research was subject to some limitations. First, there are no records in the SEER database for certain common variables related to a prognosis, such as chemotherapy status, smoking history, and vaccine status. Second, the data used in this study were for patients diagnosed with penile cancer between 2004 and 2015, and so the relatively short follow-up period might have also affected the estimation of cumulative incidence. Finally, because this study is the first to use a competing-risks model for risk assessment of penile cancer patients, further research is needed to validate its findings.

In conclusion, this study established a competing-risks analysis model for the first time based on the SEER database for risk assessments of penile cancer patients. The obtained results may help clinicians to better understand penile cancer and provide these patients with more appropriate support.
ACKNOWLEDGMENTS

This study was supported by the National Social Science Foundation of China (No. 16BGL183) and the Research Fund of Health Bureau of Xi’an (No. QFO1330).

CONFLICT OF INTEREST

The author reports no conflicts of interest in this work.

ORCID

Jun Lyu https://orcid.org/0000-0002-2237-8771

REFERENCES

1. German R, Thompson T, Stewart S, Wingo P. Distribution of male genital system cancers (MGSC), United States – 1999–2001. Ann Epidemiol. 2005;15:633-634.

2. Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR. Incidence trends in primary malignant penile cancer. Urologic Oncol: Semin OrI Invest. 2007;25:361-367.

3. Bray F, Klint Å, Gislum M, et al. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol. 2010;49:644-654.

4. Pham MN, Deal AM, Ferguson JE, et al. Contemporary survival trends in penile cancer: results from the national cancer database. Urol Oncol: Semin OrI Invest. 2017;35:671-674.

5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: Cancer J Clin. 2016;66(1):7-30.

6. Ornellas AA. Management of penile cancer. J Surg Oncol. 2008;97:199-200.

7. Chaux A, Velazquez EF, Algaba F, Ayala G, Cubilla AL. Developments in the pathology of penile squamous cell carcinomas. Urology. 2010;76:S7-S14.

8. Goodman MT, Hernandez BY, Shvetsov YB. Demographic and pathologic differences in the incidence of invasive penile cancer in the United States, 1995–2003. Cancer Epidemiol Biomark Prev. 2007;16:1833-1839.

9. Persson B, Sjödin J, Holmberg L, et al. The national penile cancer register in sweden 2000–2003. Scand J Urol Nephrol. 2009;41:278-282.

10. Souza M, Zacchi SR, Viana K, Souza C, Zandonade E, Amorim M. Survival analysis of penile cancer patients treated at a tertiary oncology hospital. Ciência & Saúde Coletiva. 2018;23:2479-2486.

11. Torbrand C, Wigertz A, Drevin L, et al. Socioeconomic factors and penile cancer risk and mortality. A population-based study. BJU Int. 2017;119:254-260.

12. Eguchi T, Bains S, Lee M, et al. Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung cancer: a competing risks analysis. J Clin Oncol. 2017;35:281-290.

13. David HA. The theory of competing risks. Australian J Statistics. 1976;3:101-110.

14. van Walraven C, McAlister FA. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals. J Clin Epidemiol. 2016;69:170-173.e8.

15. Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The surveillance, epidemiology, and end results (SEER) program and pathology. Am J Surgical Pathol. 2016;40:94-102.

16. Healy MA, Morris AM, Abrahamse P, Ward KC, Iatoi V, Veenstra CM. The accuracy of chemotherapy ascertained among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer. 2018;18(1):481.

17. Haller B, Schmidt G, Ulm K. Applying competing risks regression models: an overview. Lifetime Data Anal. 2013;19:33-58.

18. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389-2430.

19. Fine JP, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Statistical Assoc. 1999;94(446):496-509.

20. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244-256.

21. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40:381-387.

22. Moriña D, Navarro A. Competing risks simulation with the survsim R package. Commun Stat-Simul Computation. 2017;46:5712-5722.

23. Southern DA, Faris PD, Brant R, et al. Kaplan–Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol. 2006;59:1110-1114.

24. Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: the importance of multistate models and competing risks analysis. Hepatology. 2015;62:292-302.

25. Johnstone P, Spiess PE, Giuliano AR. New directions in penile cancer. Lancet Oncol. 2019;20:16-17.

26. Stratton K. A contemporary review of hpv and penile cancer. Oncology. 2016;3:245-249.

27. Sharma P, Ashouri K, Zargar-Shoshtari K, Luchey AM, Spiess PE. Racial and economic disparities in the treatment of penile squamous cell carcinoma: results from the national cancer database. Urologic Oncol: Semin Ori Invest. 2016;34:122-129.

28. Slopinick EA, Kim SP, Kiechle JE, Gonzalez CM, Zhu H, Abouassaly R. Racial disparities differ for African Americans and Hispanics in the diagnosis and treatment of penile cancer. Urology. 2016;96:22-28.

29. Li Z, Guo S, Wu Z, et al. Proposal for reclassification of N staging in penile cancer patients, based on number of positive lymph nodes. BJU International. 2018;23:2479-2486.

30. Soodana-Prakash N, Koru-Sengul T, Miao F, et al. Lymph node inguinal adenectomy for penile cancer. Urol Oncol. 2018;36:419-471.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Yang J, Pan Z, He Y, et al. Competing-risks model for predicting the prognosis of penile cancer based on the SEER database. Cancer Med. 2019;8:7881–7889. https://doi.org/10.1002/cam4.2649